NRG-HN002, “A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer,” is nearing its accrual target. Please refer to the CTSU website for current accrual. When this study reaches target accrual, NRG Oncology will send a follow-up closure notice alerting sites that the protocol will close in 2 business days.
Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.
Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.